Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMYD2 | Q9NRG4 | 3/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19898477 | 0.90 | SMYD2 (0.36) | SMYD2CYP3A4HTTSMN1; SMN2 | |
| SCHEMBL19898753 | 0.81 | SMYD2 (0.33) | SMYD2 | |
| SCHEMBL23665772 | 0.76 | CASP3 (0.36) | SMYD2 | |
| SCHEMBL19898593 | 0.76 | CAPN1 (0.36) | SMYD2 | |
| SCHEMBL23665881 | 0.75 | SMYD2 (0.37) | SMYD2 | |
| SCHEMBL1694413 | 0.74 | SMYD2 (0.37) | SMYD2CYP3A4HTTSMN1; SMN2 | |
| SCHEMBL1694412 | 0.74 | SMYD2 (0.37) | SMYD2CYP3A4HTTSMN1; SMN2 | |
| SCHEMBL31620808 | 0.73 | CASP3 (0.35) | SMYD2 | |
| SCHEMBL5151940 | 0.72 | SRC (0.40) | SMYD2CYP3A4 | |
| SCHEMBL23665886 | 0.72 | SMYD2 (0.37) | SMYD2CYP3A4HTTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11020398-B2 | Amino-pyrrolopyrimidinone compounds and methods of use thereof | ARQULE, INC. (US) | 2021-06-01 | — | — | US | disclosed |
| EP-3504213-A1 | AMINO-PYRROLOPYRIMIDINONE COMPOUNDS AND METHODS OF USE THEREOF | ArQule, Inc. (US) | 2019-07-03 | — | — | EP | disclosed |
| WO-2018039310-A1 | AMINO-PYRROLOPYRIMIDINONE COMPOUNDS AND METHODS OF USE THEREOF | ARQULE, INC. (US) | 2018-03-01 | — | — | WO | disclosed |
| US-20180055846-A1 | AMINO-PYRROLOPYRIMIDINONE COMPOUNDS AND METHODS OF USE THEREOF | ARQULE, INC. | 2018-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11020398-B2 | Amino-pyrrolopyrimidinone compounds and methods of use thereof | BTK, SYK, LCK | SMYD2 3536/4885CYP3A4 2040/4885HTT 1875/4885 |
| US-20180055846-A1 | AMINO-PYRROLOPYRIMIDINONE COMPOUNDS AND METHODS OF USE THEREOF | BTK, SYK, LCK | SMYD2 3536/4885CYP3A4 2040/4885HTT 1875/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.